New diabetes treatment could hold key for cardiovascular disease

Monday, July 15, 2019

A newly approved treatment for type 2 diabetes is being tested as a preventative measure for cardiovascular disease by Eastern Health and Monash University.

Researchers are currently seeking participants for the clinical trial, which will evaluate the effects of a new anti-diabetic medication named Liraglutide in potentially reducing cardiovascular disease in type 2 diabetic patients.

“Patients with type 2 diabetes are at increased risk of cardiovascular disease. The overall objective is to reduce cardiovascular disease, in the form of heart attack, stroke and peripheral vascular disease,” Associate Professor Anthony Dear, Principal Investigator said.

The trial came about as the result of pre-clinical (animal) and clinical studies suggesting the new medication may prevent cardiovascular disease.

“We have a great opportunity for people with type 2 diabetes to help us identify if this treatment can protect against the development of cardiovascular disease, by participating in the clinical trial.”

People aged 35-80 years old with type 2 diabetes who do not take insulin, aspirin or any other blood thinning medications and do not have a history of heart attack, stroke or peripheral vascular disease are encouraged to apply.

The study will be undertaken over a six month period and includes eight visits to our university clinic in Box Hill. Travel expenses will be reimbursed.

Please contact Study Coordinator, Vanessa James on 9194 7573 orVanessa.James@monash.edu for more information or to apply.